SG11201706774WA - Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof - Google Patents
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereofInfo
- Publication number
- SG11201706774WA SG11201706774WA SG11201706774WA SG11201706774WA SG11201706774WA SG 11201706774W A SG11201706774W A SG 11201706774WA SG 11201706774W A SG11201706774W A SG 11201706774WA SG 11201706774W A SG11201706774W A SG 11201706774WA SG 11201706774W A SG11201706774W A SG 11201706774WA
- Authority
- SG
- Singapore
- Prior art keywords
- cars
- compositions
- methods
- chimeric antigen
- antigen receptors
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562121842P | 2015-02-27 | 2015-02-27 | |
PCT/US2016/019953 WO2016138491A1 (fr) | 2015-02-27 | 2016-02-26 | Récepteurs d'antigène chimériques (car) ciblant des tumeurs malignes hématologiques, compositions et procédés pour les utiliser |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201706774WA true SG11201706774WA (en) | 2017-09-28 |
Family
ID=56789926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706774WA SG11201706774WA (en) | 2015-02-27 | 2016-02-26 | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (3) | US10273280B2 (fr) |
EP (2) | EP4091616A1 (fr) |
JP (2) | JP7237449B2 (fr) |
KR (2) | KR102632082B1 (fr) |
CN (3) | CN107249602B (fr) |
AU (1) | AU2016225012B2 (fr) |
CA (1) | CA2977106A1 (fr) |
ES (1) | ES2923895T3 (fr) |
IL (1) | IL254141B (fr) |
PL (1) | PL3261651T3 (fr) |
SG (1) | SG11201706774WA (fr) |
TW (2) | TW202143986A (fr) |
WO (2) | WO2016138491A1 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115029362A (zh) | 2015-02-06 | 2022-09-09 | 新加坡国立大学 | 核酸、包含其的工程免疫细胞及其生产方法和用途 |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
AU2016225012B2 (en) * | 2015-02-27 | 2020-09-03 | Kevin Chen | Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof |
US10786549B2 (en) | 2015-04-23 | 2020-09-29 | Baylor College Of Medicine | CD5 chimeric antigen receptor for adoptive T cell therapy |
CN115058395A (zh) * | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
US11667691B2 (en) * | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
EP3339320A4 (fr) * | 2015-08-17 | 2019-01-23 | Seoul National University R&DB Foundation | Récepteur d'anticorps chimérique auquel est lié un anticorps anti-cotinine et utilisation de celui-ci |
EP3419618A4 (fr) * | 2016-02-26 | 2019-11-06 | iCell Gene Therapeutics, LLC | Récepteurs d'antigènes chimériques (car) ciblant des tumeurs malignes hématologiques, compositions et méthodes pour les utiliser |
WO2017213979A1 (fr) | 2016-06-06 | 2017-12-14 | St. Jude Children's Research Hospital | Récepteur d'antigène chimérique anti-cd7 et son procédé d'utilisation |
WO2018027036A1 (fr) * | 2016-08-03 | 2018-02-08 | Dipersio John F | Édition génétique des cellules car-t pour le traitement de malignités des lymphocytes t avec des récepteurs d'antigènes chimériques |
CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
KR20190085528A (ko) * | 2016-11-22 | 2019-07-18 | 싱가포르국립대학교 | T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단 |
GB201622044D0 (en) * | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
EP3575319A4 (fr) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | Molécule bifonctionnelle et son utilisation |
JP7033601B2 (ja) | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
JP2020525537A (ja) * | 2017-06-12 | 2020-08-27 | エモリー ユニバーシティー | T細胞抗原標的キメラ抗原受容体(car)、及び細胞療法での使用 |
AU2018304711A1 (en) * | 2017-07-20 | 2020-01-16 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
US20190038733A1 (en) * | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
WO2019084258A1 (fr) * | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | Procédés de conditionnement à base d'anti-cd45 et utilisations associées en combinaison avec des thérapies à base de cellules génétiquement modifiées |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
CN108220236B (zh) * | 2017-12-20 | 2020-06-30 | 中国科学院遗传与发育生物学研究所 | 一种人的nk细胞系 |
CN108060137B (zh) * | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
EP3684399A1 (fr) * | 2017-12-29 | 2020-07-29 | Cellectis | Procédé d'amélioration de la production de lymphocytes t car |
KR20240042263A (ko) * | 2018-05-22 | 2024-04-01 | 난트퀘스트, 인크. | Fc-엡실론 car |
EP3784777A4 (fr) * | 2018-05-23 | 2022-01-26 | National University of Singapore | Récepteurs antigéniques chimériques et édition génique de cd2 pour l'immunothérapie des malignités des lymphocytes t |
KR20210008408A (ko) * | 2018-05-23 | 2021-01-21 | 싱가포르국립대학교 | T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단 |
CN112867498A (zh) * | 2018-05-31 | 2021-05-28 | 华盛顿大学 | 使用嵌合抗原受体基因组编辑和转导t细胞以用于治疗t和b细胞恶性肿瘤的方法 |
WO2019245993A1 (fr) * | 2018-06-19 | 2019-12-26 | Nantcell, Inc. | Compositions et méthodes de traitement du vih |
CN112567025A (zh) * | 2018-08-10 | 2021-03-26 | 国立大学法人京都大学 | Cd3阳性细胞的制造方法 |
WO2020097193A1 (fr) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Récepteurs antigéniques chimériques pour la phagocytose |
KR102569842B1 (ko) * | 2018-11-06 | 2023-08-23 | 난트퀘스트, 인크. | 키메라 항원 수용체-변형된 nk-92 세포 |
CN109266667B (zh) * | 2018-11-06 | 2021-08-03 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd5的嵌合抗原受体及其应用 |
EP3898692A4 (fr) * | 2018-12-19 | 2022-10-19 | The Trustees of the University of Pennsylvania | Utilisation de lymphocytes t de récepteur antigénique chimérique anti-cd2/5/7 à cd2/5/7 inactivé dirigés contre des lymphomes et des leucémies à lymphocytes t |
CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
WO2020190925A1 (fr) * | 2019-03-19 | 2020-09-24 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Procédés et compositions pour la modification de lymphocytes t car déficients en cd4 et de lymphocytes t car anti-cd4 et leurs utilisations |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
WO2021046243A2 (fr) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Méthodes et compositions d'intégration génomique |
WO2021073626A1 (fr) * | 2019-10-17 | 2021-04-22 | 北京门罗生物科技有限公司 | Récepteur antigénique chimérique et lymphocytes t exprimant des récepteurs antigéniques chimériques en leur sein |
US11723950B2 (en) | 2019-10-18 | 2023-08-15 | Trustees Of Boston University | CAL-T constructs and uses thereof |
CN115190910A (zh) * | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
US20230059884A1 (en) * | 2019-12-30 | 2023-02-23 | Edigene Biotechnology Inc. | Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof |
GB202005599D0 (en) * | 2020-04-17 | 2020-06-03 | Univ London | Modulation of t cell cytotoxicity and related therapy |
WO2022061115A1 (fr) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions et procédés pour modification de cd7 |
WO2022067089A1 (fr) * | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Cellules immunitaires modifiées résistantes au fratricide et leurs méthodes d'utilisation |
JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
WO2022152186A1 (fr) * | 2021-01-12 | 2022-07-21 | 南京驯鹿医疗技术有限公司 | Récepteur antigénique chimérique (car) à domaine unique en tandem entièrement humain ciblant cd5 et son utilisation |
CN115786271A (zh) * | 2021-01-12 | 2023-03-14 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
CN112980800A (zh) * | 2021-03-08 | 2021-06-18 | 河北森朗生物科技有限公司 | Car-t细胞、其构建方法及其应用 |
CN115044617A (zh) * | 2021-03-08 | 2022-09-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
GB202105682D0 (en) * | 2021-04-21 | 2021-06-02 | Imp College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
GB202105684D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
GB202105686D0 (en) * | 2021-04-21 | 2021-06-02 | Imperial College Innovations Ltd | Chimeric antigen receptor (CAR)-T cells |
EP4332118A1 (fr) | 2021-04-29 | 2024-03-06 | Korea Research Institute of Bioscience and Biotechnology | Nouveau récepteur antigénique chimérique anti-cd5 et cellule immunitaire l'exprimant |
EP4366836A2 (fr) * | 2021-07-08 | 2024-05-15 | Medic Life Sciences Inc. | Système de criblage à haut débit pour l'identification de nouveaux médicaments et de nouvelles cibles de médicaments |
CN115989244A (zh) * | 2021-08-06 | 2023-04-18 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
AU2022380926A1 (en) * | 2021-11-04 | 2024-05-30 | Affimed Gmbh | Treatment of cancer with nk cells and multispecific engagers |
WO2023129929A1 (fr) | 2021-12-30 | 2023-07-06 | Tr1X, Inc. | Lymphocytes t cd4+ exprimant il-10 et récepteurs antigéniques chimériques et leurs utilisations |
CN114685662B (zh) * | 2022-03-30 | 2022-12-27 | 河北森朗生物科技有限公司 | 抗cd7纳米抗体、衍生物及其在肿瘤治疗中的应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
CA2386270A1 (fr) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Genes de voies d'interference d'arn en tant qu'outils d'interference genetique ciblee |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001096584A2 (fr) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Matieres et procedes de lutte contre les nematodes |
US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
EP1539234A4 (fr) | 2002-09-05 | 2006-02-15 | Medimmune Inc | Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2 |
WO2005108415A2 (fr) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Molecules associees aux membranes |
US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
EP1777294A1 (fr) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion |
CA2655471C (fr) | 2006-06-12 | 2017-02-14 | Centocor, Inc. | Procede de detection de l'activite de l'il-16 et modulation de l'activite de l'il-16 basee sur les niveaux de rantes |
CA2668208C (fr) * | 2006-11-02 | 2017-09-12 | Daniel J. Capon | Immunoglobulines hybrides presentant des parties mobiles |
BRPI0909179A2 (pt) * | 2008-03-13 | 2015-08-25 | Biotest Ag | Composição farmacêutica, e, método de tratamento de uma doença autoimune. |
WO2010085660A2 (fr) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Vecteurs viraux codant pour de multiples polypeptides non viraux très homologues et leur utilisation |
MX342907B (es) | 2009-05-13 | 2016-10-17 | Genzyme Corp * | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. |
WO2010132697A2 (fr) * | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Procédés et compositions de traitement |
EP2325322A1 (fr) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Particules de vecteur rétroviral et leurs procédés de génération et utilisation |
WO2012136231A1 (fr) | 2010-09-08 | 2012-10-11 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukine 15 utilisée comme marqueur sélectionnable pour le transfert de gènes dans des lymphocytes |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
US8785190B2 (en) * | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
RU2016147206A (ru) * | 2011-04-15 | 2018-10-19 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
WO2013026839A1 (fr) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants |
EP2814846B1 (fr) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
WO2013126712A1 (fr) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Topicompositions et procédés pour produire une population de lymphocytes t tenaces utiles dans le traitement du cancer |
TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
WO2013169691A1 (fr) * | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
WO2014055657A1 (fr) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques |
TWI630215B (zh) | 2012-12-18 | 2018-07-21 | 美國洛克菲勒大學 | 用於hiv預防及治療的醣修飾抗cd4抗體 |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
JP6450690B2 (ja) | 2013-02-15 | 2019-01-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | キメラ抗原受容体及びその使用方法 |
EP3623380A1 (fr) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Ciblage de cellules cytotoxiques avec récepteurs chimériques pour immunothérapie adoptive |
CN107058354A (zh) * | 2013-04-01 | 2017-08-18 | 科济生物医药(上海)有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
EP4364809A2 (fr) | 2013-05-13 | 2024-05-08 | Cellectis | Récepteur antigénique chimérique spécifique de cd19 et ses utilisations |
NZ720161A (en) | 2013-11-04 | 2022-07-29 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
KR101962524B1 (ko) | 2013-11-21 | 2019-07-17 | 유씨엘 비즈니스 피엘씨 | 세포 |
US20170145108A1 (en) | 2014-02-05 | 2017-05-25 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
EP3505623A1 (fr) | 2014-02-14 | 2019-07-03 | Cellectis | Cellules destinées à l'immunothérapie modifiées pour cibler un antigène présent à la fois sur les cellules immunitaires et les cellules pathologiques |
JP6788573B6 (ja) | 2014-04-10 | 2020-12-16 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | メトトレキサートによる選択と組み合わせたSleeping Beautyトランスポゾンによる遺伝子改変T細胞の製造 |
US10301370B2 (en) | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
DE112014006656B4 (de) | 2014-05-14 | 2018-05-17 | Carsgen Therapeutics Limited | Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins |
CN104004092B (zh) * | 2014-06-05 | 2015-07-29 | 深圳市第三人民医院 | 单基因编码的双或多价特异性抗hiv免疫粘附素 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN115029362A (zh) | 2015-02-06 | 2022-09-09 | 新加坡国立大学 | 核酸、包含其的工程免疫细胞及其生产方法和用途 |
AU2016225012B2 (en) * | 2015-02-27 | 2020-09-03 | Kevin Chen | Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof |
US10786549B2 (en) * | 2015-04-23 | 2020-09-29 | Baylor College Of Medicine | CD5 chimeric antigen receptor for adoptive T cell therapy |
-
2016
- 2016-02-26 AU AU2016225012A patent/AU2016225012B2/en active Active
- 2016-02-26 SG SG11201706774WA patent/SG11201706774WA/en unknown
- 2016-02-26 IL IL254141A patent/IL254141B/en unknown
- 2016-02-26 US US15/551,862 patent/US10273280B2/en active Active
- 2016-02-26 CN CN201680011435.3A patent/CN107249602B/zh active Active
- 2016-02-26 CN CN202111206050.1A patent/CN114230670A/zh active Pending
- 2016-02-26 WO PCT/US2016/019953 patent/WO2016138491A1/fr active Application Filing
- 2016-02-26 PL PL16756524.1T patent/PL3261651T3/pl unknown
- 2016-02-26 CA CA2977106A patent/CA2977106A1/fr active Pending
- 2016-02-26 EP EP22171209.4A patent/EP4091616A1/fr active Pending
- 2016-02-26 EP EP16756524.1A patent/EP3261651B1/fr active Active
- 2016-02-26 JP JP2017564321A patent/JP7237449B2/ja active Active
- 2016-02-26 KR KR1020177027386A patent/KR102632082B1/ko active IP Right Grant
- 2016-02-26 ES ES16756524T patent/ES2923895T3/es active Active
- 2016-02-26 KR KR1020247003304A patent/KR20240018680A/ko active IP Right Grant
- 2016-03-01 TW TW110126850A patent/TW202143986A/zh unknown
- 2016-03-01 TW TW105106256A patent/TWI823829B/zh active
- 2016-07-15 WO PCT/US2016/042591 patent/WO2017146767A1/fr active Application Filing
- 2016-07-15 CN CN201680082302.5A patent/CN109414428A/zh active Pending
-
2019
- 2019-04-01 US US16/371,501 patent/US20190345217A1/en not_active Abandoned
-
2021
- 2021-02-19 JP JP2021025246A patent/JP7379399B2/ja active Active
-
2023
- 2023-03-14 US US18/121,101 patent/US20240124547A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3261651A4 (fr) | 2018-11-07 |
TW201706295A (zh) | 2017-02-16 |
JP2018513692A (ja) | 2018-05-31 |
EP3261651A1 (fr) | 2018-01-03 |
TWI823829B (zh) | 2023-12-01 |
JP7237449B2 (ja) | 2023-03-13 |
EP3261651B1 (fr) | 2022-05-04 |
EP4091616A1 (fr) | 2022-11-23 |
IL254141B (en) | 2022-07-01 |
CN114230670A (zh) | 2022-03-25 |
JP2021078514A (ja) | 2021-05-27 |
CN107249602B (zh) | 2021-09-28 |
KR20240018680A (ko) | 2024-02-13 |
AU2016225012A1 (en) | 2017-08-31 |
US20240124547A1 (en) | 2024-04-18 |
US10273280B2 (en) | 2019-04-30 |
WO2017146767A1 (fr) | 2017-08-31 |
PL3261651T3 (pl) | 2022-08-22 |
US20180066034A1 (en) | 2018-03-08 |
CN109414428A (zh) | 2019-03-01 |
CA2977106A1 (fr) | 2016-09-01 |
KR20180002604A (ko) | 2018-01-08 |
AU2016225012B2 (en) | 2020-09-03 |
IL254141A0 (en) | 2017-10-31 |
TW202143986A (zh) | 2021-12-01 |
KR102632082B1 (ko) | 2024-02-02 |
US20190345217A1 (en) | 2019-11-14 |
ES2923895T3 (es) | 2022-10-03 |
CN107249602A (zh) | 2017-10-13 |
JP7379399B2 (ja) | 2023-11-14 |
WO2016138491A1 (fr) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254141A0 (en) | Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use | |
IL287718A (en) | Chimeric antigen receptors (cars), preparations and methods for their use | |
IL264607A (en) | Chimeric receptors for bcma-directed antigens and methods of using them | |
SG11202000555UA (en) | Chimeric antigen receptors (cars), compositions and methods thereof | |
HK1259190A1 (zh) | 嵌合抗原受體相關的方法和組合物 | |
IL292222A (en) | her2-targeted chimeric antigen receptors | |
HK1249405A1 (zh) | 抗dll3嵌合抗原受體及其使用方法 | |
IL255336A0 (en) | Chimeric antigen receptors and methods of using them | |
PL3443096T3 (pl) | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych | |
IL263626A (en) | Chimeric antigen receptors and methods for use | |
IL252295A0 (en) | Chimeric antigen receptors and methods of using them | |
EP3474867A4 (fr) | Récepteurs d'antigènes chimériques (car), compositions et procédés associés | |
IL250831A0 (en) | Antibodies and chimeric antigen receptors specific for cd19, preparations containing them and their uses | |
EP3259352A4 (fr) | Récepteurs antigéniques chimériques et leurs utilisations | |
IL265438A (en) | Chimeric antigen receptors and jewelry and methods of using them | |
IL252604B (en) | Chimeric antigen receptors and their misuse | |
ZA201703471B (en) | Anti-cldn chimeric antigen receptors and methods of use | |
EP3347474A4 (fr) | Récepteurs d'antigènes chimériques et leurs utilisations | |
HK1255312A1 (zh) | 抗原受體及其用途 | |
IL271144A (en) | Methods and compositions for reducing the immunogenicity of chimeric Notch receptors | |
EP3419618A4 (fr) | Récepteurs d'antigènes chimériques (car) ciblant des tumeurs malignes hématologiques, compositions et méthodes pour les utiliser | |
AU2016222891A1 (en) | Anti-DLL3 chimeric antigen receptors and methods of use |